Haem oxygenase-1 (HO-1) could provide cytoprotection against various inflammatory diseases. However, the mechanisms underlying the protective effect of CO-releasing molecule-2 (CORM-2)-induced HO-1 expression against TNF-α-induced inflammatory responses in human pulmonary alveolar epithelial cells (HPAEpiCs) remain unknown.
Introduction
Injuries of alveolar epithelial cells alter lung respiratory function resulting in various lung diseases such as chronic obstructive pulmonary disease (COPD), which is implicated in pulmonary inflammation (Barnes, 2008) . During the inflammation, an up-regulation of adhesion molecules, such as intercellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1), on the surface of endothelial cells or multiple airway resident cells contribute to the recruitment of polymorphonuclear cells (PMNs) to the regions of inflammation in response to TNF-α or IL-1β. Therefore, the attenuation of the recruitment of PMNs may be an effective therapeutic strategy for inflammation-related pathologies. However, the induction of haem oxygenase-1 (HO-1) occurs as an adaptive response and has beneficial effects in several inflammatory conditions and has been implicated in many clinically relevant diseases (Lee et al., 2008) . The main function of HO-1 is to catalyse the rate-limiting step of haem degradation, resulting in the formation of iron, carbon monoxide (CO), and biliverdin, which is subsequently converted to bilirubin by biliverdin reductase (Soares and Bach, 2009 ). HO-1 exerts anti-inflammatory and antiapoptotic functions which are mediated via a CO-dependent mechanism, since the administration of low concentrations of CO showed similar effects to HO-1 (Slebos et al., 2003) . Since CO inhalation cannot be accurately regulated and prolonged exposure may be toxic to tissues, CO-releasing molecules (CORMs) were developed to allow selective delivery and release of CO from a nontoxic pro-drug. A transition metal carbonyl-based compound, CORM-2, can efficiently release controlled amounts of CO and is a safer alternative to inhaled CO (Constantin et al., 2012) . Studies have demonstrated that the expression of HO-1 is regulated by CORM-2 in astrocytes, suggesting the possibility of amplified HO-1/ CO axis on tissue repair (Choi et al., 2010) . The beneficial effects of HO-1/CO are conveyed through the inhibition of inflammatory, apoptotic and proliferative processes. Thus, in this study, we attempted to investigate the mechanisms involved in CORM-2-induced HO-1 expression in human pulmonary alveolar epithelial cells (HPAEpiCs) and the effects of HO-1 against TNF-α-induced accumulation of PMNs.
The expression of the HO-1 gene is tightly regulated; inhibition of non-receptor tyrosine kinase, PYK2, by PF431396 was found to abolish HO-1 expression in human cardiomyocytes (Chien et al., 2015) . And phosphorylation of PKC is involved in parthenolide-induced HO-1 expression in cholangiocarcinoma (Yun et al., 2010) . Selective inhibition of PKC and ERK1/2 (p44/42 MAPK) by calphostin C or PD98059 down-regulated HO-1 expression in cadmiumstimulated lymphocytes (B cell line BJAB) (Nemmiche et al., 2012) . Moreover, curcumin has been shown to dosedependently increase HO-1 expression through the activation of PKCα (Hsu et al., 2008) . Ferulic acid also induce HO-1 expression via ERK1/2 (Ma et al., 2011) . However, whether PYK2, PKCα and ERK1/2 participate in CORM-2-induced HO-1 expression in HPAEpiCs remains largely unknown. Thus, whether PYK2, PKCα and ERK1/2 are involved in HO-1 expression was investigated in CORM-2-stimualted HPAEpiCs.
Activator protein 1 (AP-1) is a heterodimer of Fos and Jun oncoproteins and has been shown to bind to the tetradecanoylphorbol-13-acetate response element (Wagner and Eferl, 2005) , which is responsible for the transcriptional activation of various genes via activation of PKCs, protein tyrosine kinase and MAPKs. In our previous studies, sphingosine-1-phosphate or TNF-α was shown to regulate ICAM-1 or cPLA 2 gene expression via MAPK-dependent activation of AP-1 in HPAEpiCs (Lee et al., 2013a; Lin et al., 2015) . Moreover, HO-1 expression induced by sevoflurane is mediated through AP-1 in the rat liver (Schwer et al., 2010) . Thus, the role of AP-1 in CORM-2-induced HO-1 expression was also investigated in HPAEpiCs.
From the experiments performed in this study, we showed that CORM-2-induced increase in HO-1 expression is mediated through AP-1 activation in HPAEpiCs. These findings suggest that CORM-2-induced HO-1 expression is, at least in part, mediated through a PYK2/PKCα/ERK1/2-dependent AP-1 pathway, which then attenuates TNF-α-induced inflammatory responses.
Methods

Animal care and experimental procedures
Male ICR mice aged 6-8 weeks were purchased from the National Laboratory Animal Centre (Taipei, Taiwan) and handled according to the guidelines of Animal Care Committee of Chang Gung University and NIH Guides for the Care and Use of Laboratory Animals. Animal studies are reported in accordance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Animals were assigned randomly to different experimental groups for all in vivo studies. Data collection and evaluation of all in vivo and in vitro experiments were performed blindly of the group identity. Mice were divided into seven groups, five mice in each group per cage and kept in standard individually ventilated cages in an animal facility under standardized conditions (12 h light/dark cycle, 21-24°C, humidity of 50-60%) with food and water ad libitum. For the in vivo treatment, zinc protoporphyrin IX (ZnPPIX) (Fest et al., 2016) and CORM-2 were dissolved in DMSO at a concentration of 10 and 50 mg·mL À1 , respectively, and further diluted in PBS before injection. The final dosages for ZnPPIX and CORM-2 were weight) was placed at the back of the throat and aspirated into lungs. After 24 h, mice were killed under isoflurane anaesthesia and then specimens were harvested. BAL fluid was obtained through a tracheal cannula using 1 mL aliquots of ice-cold PBS solution. BAL fluid was centrifuged at 500× g at 4°C, and cell pellets were washed and resuspended in PBS. Leukocyte count was determined by a haemocytometer, as previously described (Matsumoto et al., 2006) . To examine the levels of HO-1 and VCAM-1 expression in the mice treated with or without CORM-2 followed by treatment with TNF-α, lung tissues were collected, homogenized and subjected to Western blot to determine the levels of VCAM-1, HO-1 and β-actin protein, as previously described (Matsumoto et al., 2006) .
Cell culture and treatment
HPAEpiCs were purchased from the ScienCell Research Laboratories (San Diego, CA, USA) and grown as previously described (Lee et al., 2013b) .
Transient transfection with siRNAs
Human siRNAs of PKCα (L-003523-00-0020) was from Dharmacon (Lafayette, CO, USA); scrambled, PYK2 (SASI_Hs01_00032249) and p42 (SASI_Hs01_00058601) were from Sigma (St. Louis, MO, USA); and c-Fos (FOS-HSS103799) was from Invitrogen (Carsbad, CA, USA). Transient transfection of siRNAs (100 nM) was performed by using a GeneMute reagent according to the manufacturer's instructions from SignaGen Lab (Rockville, MD, USA).
Real-time RT-PCR
Total RNA was extracted by using TRIzol reagent. The mRNA was reverse-transcribed into cDNA and analysed by real-time PCR. Each PCR was performed using 100 ng of cDNA and TaqMan Human GAPDH was used as a control to verify the quality of the cDNA template. Real-time PCR was performed and analysed using a StepOnePlus quantitative PCR instrument (Applied Biosystems). The levels of HO-1 expressed were determined by normalizing to GAPDH expression. Relative gene expression was determined by the ΔΔCt method (Livak and Schmittgen, 2001) , where Ct denotes threshold cycle. All experiments were performed in five independent experiments and determined in triplicate.
Preparation of cell extracts and Western blot
Growth-arrested HPAEpiCs were incubated with CORM-2 at 37°C for the indicated time intervals. The cells were washed, scraped, collected and centrifuged at 45 000× g at 4°C for 1 h to yield the whole cell extract, as previously described (Lee et al., 2008) . Samples were denatured, subjected to SDS-PAGE using a 12% (w . v -1 ) running gel and transferred to a nitrocellulose membrane. Membranes were incubated with an anti-HO-1 antibody (1:1000) for 24 h and then incubated with an anti-rabbit horseradish peroxidase antibody (1:1000) for 1 h. The immunoreactive bands were detected by ECL reagents and captured by a UVP BioSpectrum 500 Imaging System (Upland, CA, USA). The image densitometry analysis was quantified by use of UN-SCAN-IT gel software (Orem, UT, USA).
Cell viability
For measurement of cell viability, cells were seeded into 96-well plates, cultured overnight in DMEM /F-12 containing 10% (v . v -1 ) FBS and then treated with CORM-2 (0-100 μM) or pharmacological inhibitors for 24 h. Cell viability was determined by the 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.
Statistical analysis of data
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All the data are expressed as the mean or mean ± SEM of five individual experiments performed in duplicate or triplicate. The significance of differences between two groups was determined by Student's paired two-tailed t-test for Western blot data. For all other statistical analyses and comparisons of multiple groups, a GraphPad Prism Programme (GraphPad, San Diego, CA, USA) using ANOVA followed by Tukey's post hoc test has been used. In all cases, P < 0.05 was considered to indicate statistical significance. Error bars were omitted when they fell within the dimensions of the symbols.
Materials
DMEM/F-12 medium, FBS, TRIzol reagent and PLUSLipofectamine were from Invitrogen (Carlsbad, CA, USA). PF431396 (Han et al., 2009a,b) , Ro-318220, Gö6976 (Martiny-Baron et al., 1993), Gö6983 (Stempka et al., 1999) , U0126 (Favata et al., 1998) and Tanshinone IIA (Jang et al., 2003) were from Biomol (Plymouth Meeting, PA, USA). ZnPPIX (Fest et al., 2016) was from Caynman Chemical (Ann Arbor, MI, USA). Luciferase assay kit was from Promega (Madison, WI, USA). Anti-HO-1, anti-β-actin, anti-PYK2, anti-PKCα, anti-Gαs, anti-GAPDH, anti-p42, anti-c-Fos and anti-ICAM-1 antibodies were from Santa Cruz (Santa Cruz, CA, USA). Anti-phospho-PYK2 (#3291), anti-phospho-PKCα (#9375) and anti-phospho-ERK1/2 (#9101) antibodies were from Cell Signaling (Danvers, MA, USA). Tricarbonyldichlororuthenium (II) dimer (CORM-2) and other chemicals were from Sigma (St. Louis, MO, USA). TaqMan PCR Master Mixture was from Thermo Fisher Scientific Inc (Waltham, MA, USA). SDS-PAGE reagents were from MDBio Inc (Taipei, Taiwan).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
CORM-2 inhibits TNF-α-induced lung inflammation in mice
In our previous studies, TNF-α has been shown to induce the expression of VCAM-1 or ICAM-1 in various cell types 2013b) . TNF-α markedly induced VCAM-1 protein expression in HPAEpiCs and leukocyte count in BAL fluid, which were also reduced by CORM-2 ( Figure 1A , B). We found that treatment of mice with ZnPPIX alone had no effect on the levels of HO-1 and VCAM-1 expression, and treatment with ZnPPIX plus TNF-α enhanced the VCAM-1 expression similar to that of treatment with TNF-α alone. However, we noticed that pretreatment with ZnPPIX reversed the inhibitory effect of HO-1 (approximate 85%) on TNF-α-induced increase in VCAM-1 expression and leukocytes in mice challenged with TNF-α (Figure 1, B) . These results suggest that the CORM-2-induced suppression of the TNF-α-mediated inflammatory responses is, at least in part, mediated through an up-regulation of HO-1.
Effects of CORM-2 on HO-1 expression and cell viability
Our previous studies indicated that CORM-2 up-regulates HO-1 expression in various cell types (Chi et al., 2014; . Here, we evaluated the effects of CORM-2 on HO-1 expression in HPAEpiCs. The data showed that CORM-2 markedly increased the expression of HO-1 protein and mRNA in a time-and concentration-dependent manner (Figure 2A , B). CORM-2 significantly enhanced HO-1 protein expression within 6 h and this reached a maximal response within 16 h during the period of observation. In addition, CORM-2 induced a maximal expression of HO-1 mRNA within 4-6 h. We also examined the effects of CORM-2 (0-100 μM) on the cell viability of HPAEpiCs by using an MTT assay. As shown in Figure 2C , CORM-2 HO-1 attenuates TNF-α-induced VCAM-1 expression BJP (10 and 50 μM) had no effects on the cell viability of HPAEpiCs. However, only 100 μM CORM-2 significantly decreased the cell viability of HPAEpiCs. Thus, 50 μM CORM-2 was used for the following experiments.
Involvement of PYK2 in CORM-2-induced HO-1 expression PYK2 has been shown to act as a critical player in the signal transduction pathways that regulate the expression of several genes and cellular functions (Cheng et al., 2002; Schindler et al., 2007; Lipinski and Loftus, 2010; Yang et al., 2013) . Here, we investigated whether PYK2 was involved in CORM-2-induced increase in HO-1 expression. As shown in Figure 3A , CORM-2-induced HO-1 protein levels were markedly reduced by pretreatment with the inhibitor of PYK2 (PF431396) in a concentration-dependent manner. In addition, CORM-2-induced HO-1 mRNA expression was also inhibited by PF431396 ( Figure 3B ). We further confirmed the role of PYK2 in CORM-2-induced HO-1 expression by using PYK2 siRNA. As shown in Figure 3C , transfection with PYK2 siRNA knocked down the PYK2 protein level and significantly reduced CORM-2-induced HO-1 expression in HPAEpiCs. Finally, we investigated whether the involvement of PYK2 in HO-1 expression was mediated through PYK2 phosphorylation. We observed that CORM-2 timedependently stimulated PYK2 phosphorylation and this effect was reduced by PF431396 ( Figure 3D ). These results suggest that CORM-2-induced HO-1 expression is mediated through PYK2 phosphorylation in HPAEpiCs.
CORM-2 induces HO-1 expression via PKCα
PKCs have been shown to regulate the expression of several genes associated with pathophysiological responses in various cell types (Yang et al., 2009; Lee and Yang, 2012; Lee et al., 2013a) . Here, we investigated whether PKCα was involved in CORM-2-induced HO-1 expression. As shown in Figure 4A , pretreatment with the inhibitor of pan-PKC (Ro-318 220) or PKCα (Gö6976 or Gö6983) markedly reduced CORM-2-induced HO-1 protein levels. In addition, CORM-2-induced HO-1 mRNA levels were also inhibited by these PKC inhibitors ( Figure 4B ). We further confirmed the role of PKCα in CORM-2-induced HO-1 expression by using PKCα siRNA. As shown in Figure 4C , transfection with PKCα siRNA knocked down PKCα protein levels and significantly reduced CORM-2-induced HO-1 expression in these cells. The relationship between PYK2 and PKCα was differentiated in HPAEpiCs challenged with CORM-2. We observed that CORM-2 time-dependently induced an increase in PKCα phosphorylation, which was reduced by PF431396, Gö6983 or Gö6976 ( Figure 4D ). However, pretreatment with Gö6976 had no effect on CORM-2-stimulated PYK2 phosphorylation ( Figure 3D ). These results suggest that CORM-2-induced HO-1 expression is mediated through a PYK2/PKCα cascade in HPAEpiCs.
CORM-2 induces HO-1 expression through ERK1/2
MAPKs exert multiple effects on the expression of various genes and cellular functions. Previously, ERK1/2 has also been shown to be involved in the induction of HO-1 (Cheng et al., 2010) . Here, we investigated whether ERK1/2 was involved in CORM-2-induced HO-1 expression in HPAEpiCs. As shown in Figure 5A , pretreatment with the inhibitor of MEK1/2 (U0126) markedly reduced CORM-2-induced HO-1 protein levels. In addition, CORM-2-induced HO-1 mRNA levels were also inhibited by U0126 ( Figure 5B ). To confirm the role of ERK1/2 in CORM-2-induced HO-1 expression, as shown in Figure 5C , transfection with p42 siRNA knocked down p42 protein level and significantly reduced CORM-2-induced HO-1 expression in these cells. Finally, we observed whether the role of ERK1/2 in CORM-2-induced responses was mediated through its phosphorylation. We found that CORM-2 time-dependently stimulated ERK1/2 phosphorylation ( Figure 5D ). PYK2 and PKCα have been shown to be involved in ERK1/2 activation (Yao et al., 2009; Anfuso et al., 2014) . We further differentiated the relationship among PYK2, PKCα and ERK1/2 in CORM-2-challenged HPAEpiCs. As shown in Figure 5D , pretreatment with U0126, PF431396 or Gö6983 inhibited CORM-2-stimulated ERK1/2 phosphorylation. These results suggested that CORM-2-induced HO-1 expression is mediated through a PYK2/PKCα/ERK1/2 signalling pathway in HPAEpiCs.
CORM-2 induces HO-1 expression via AP-1
AP-1 is an important transcription factor regulated by ERK1/2 leading to the expression of various genes including HO-1 (Wright et al., 2009) . In this study, we investigated whether AP-1 was involved in CORM-2-induced HO-1 expression in HPAEpiCs. As shown in Figure 6A , pretreatment with the (1 μM) or PF431396 (10 μM) for 1 h and then incubated with 50 μM CORM-2 for the indicated time intervals. The levels of phospho-PKCα were observed. Data are expressed as mean ± SEM of five independent experiments. *P < 0.05, as compared with the cells exposed to CORM-2 alone for the indicated time point.
inhibitor of AP-1 (Tanshinone IIA) markedly reduced CORM-2-induced HO-1 protein levels. In addition, the CORM-2-induced increase in HO-1 mRNA levels was also inhibited by Tanshinone IIA ( Figure 6B ). Indeed, we observed that CORM-2 time-dependently induced an increase in c-Fos mRNA expression with a maximal response within 2 h ( Figure 6C ), which was attenuated by pretreatment with PF431396, Gö6976, Gö6983 or U0126 ( Figure 6D ). To confirm that c-Fos is involved in CORM-2-induced HO-1 expression, as shown in Figure 6E , transfection with c-Fos siRNA knocked down c-Fos protein level and significantly reduced CORM-2-induced increase in HO-1 expression in HPAEpiCs. These results suggest that CORM-2-induced HO-1 expression is mediated through an AP-1-dependent mechanism in HPAEpiCs.
Discussion
Several lines of evidence demonstrate that an elevation of CO generated from the catabolism of haem by HO protects against the inflammatory responses in pulmonary diseases (Constantin et al., 2012) . The anti-inflammatory properties of CO and CORMs have been demonstrated in a variety of animal models of inflammation, suggesting that they could possibly be used as a therapeutic for inflammatory diseases. However, the molecular mechanisms by which CORM-2 induces HO-1 expression are not fully understood in HPAEpiCs.
Here, we observed that pretreatment with CORM-2 inhibited TNF-α-induced lung inflammatory responses by inducing an increase in the expression of HO-1 induction. Furthermore, the application of pharmacological inhibitors and genetic
Figure 5
CORM-2 induces HO-1 expression via ERK1/2 (p44/42 MAPK). (A) HPAEpiCs were pretreated with U0126 (0.1, 1 and 10 μM) for 1 h and then incubated with 50 μM CORM-2 for 16 h. The levels of HO-1 protein were determined. (B) Cells were pretreated with U0126 (10 μM) for 1 h and then incubated with 50 μM CORM-2 for 6 h. The HO-1 mRNA levels were determined by real-time PCR. (C) Cells were transfected with either scrambled or ERK2 (p42) siRNA and then incubated with 50 μM CORM-2 for 16 h. The levels of ERK2 (p42) and HO-1 protein were determined. (D) Cells were pretreated with U0126 (10 μM), PF431396 (3 μM) or Gö6983 (10 μM) for 1 h and then incubated with 50 μM CORM-2 for the indicated time intervals. The levels of phospho-ERK1/2 (p44/42) were observed. Data are expressed as mean ± SEM of five independent experiments. *P < 0.05, as compared with the cells exposed to CORM-2 alone.
silencing through transfection with siRNA of PYK2, PKCα, p42 or c-Fos attenuated the CORM-2-induced increase in HO-1 expression. The present study clearly demonstrated that HO-1 expression induced by CORM-2 is mediated through a PYK2/PKCα/ERK1/2/AP-1 pathway and this suppresses the inflammatory responses triggered by TNF-α in both in vitro and in vivo studies ( Figure 6F ).
All cells catabolize haem using one of two isoforms of HO, HO-1 or HO-2, which are the inducible and constitutive isoforms respectively (Motterlini and Foresti, 2014) . HO-1 is activated within hours in a host exposed to various stressors including oxidants, pathogens, chemokines and growth factors (Ryter and Choi, 2009; Wegiel et al., 2013) . The induction of HO-1 expression by various stimuli has anti- Figure 6 CORM-2 induces HO-1 expression via AP-1. (A) HPAEpiCs were pretreated with Tanshinone IIA (TSA IIA; 0.01, 0.1 and 1 μM) for 1 h and then incubated with 50 μM CORM-2 for 16 h. The levels of HO-1 protein were determined. (B) Cells were pretreated with Tanshinone IIA (1 μM) for 1 h and then incubated with 50 μM CORM-2 for 6 h. The HO-1 mRNA levels were determined by real-time PCR. (C, D) Cells were pretreated without or with PF431396 (3 μM), Gö6976 (10 μM), Gö6983 (10 μM) or U0126 (10 μM) for 1 h and then incubated with 50 μM CORM-2 for 2 h. The c-Fos mRNA levels were measured by real-time PCR. (E) Cells were transfected with scrambled or c-Fos siRNA and then incubated with 50 μM CORM-2 for 16 h. The levels of c-Fos, HO-1 and β-actin protein were determined. Data are expressed as mean ± SEM of five independent experiments. *P < 0.05, as compared with the cells exposed to CORM-2 alone (A, B, D) or vehicle (0.5% DMSO) alone (C). (F) Schematic signalling pathways are involved in CORM-2-induced HO-1 expression. CORM-2 activates the PYK2/PKCα pathway to enhance ERK1/2 (p44/42 MAPK) phosphorylation, which in turn initiates the activation of AP-1 and ultimately induces HO-1 expression in HPAEpiCs. Moreover, pretreatment with CORM-2 inhibits TNF-α-induced lung inflammation via the induction of HO-1.
inflammatory and anti-apoptotic effects in various cell types. CO generated by HO-1 regulates, either positively or negatively, the intercellular and intracellular networks and communication within the tissues and organ systems, allowing them to respond appropriately to the stressor or change in environmental cues. Regulation of the HO-1 gene is predominant at the transcriptional level. Various transcription factors interact with DNA binding domains in the HO-1 promoter to regulate gene transcription. A number of signalling molecules have been ascertained to be involved in regulating HO-1 expression.
HO-1 expression has been shown to be mediated through the activation of non-receptor tyrosine kinases including PYK2 in various types of cells (Choi and Alam, 1996; Han et al., 2009a,b; Chi et al., 2015; Yang et al., 2015) . We noted that CORM-2-induced HO-1 expression was attenuated by PF431396 or by transfection with PYK2 siRNA, confirming that PYK2 is involved in HO-1 expression through the phosphorylation of PYK2 in HPAEpiCs. Moreover, PKCs also play important roles in many cellular responses in the lung, including permeability, contraction, migration, hypertrophy, proliferation, apoptosis and secretion (Lee and Yang, 2012; Lee et al., 2013a) . We found that the inhibition of PKCα markedly reduced CORM-2-induced HO-1 expression, which was confirmed by using a pharmacological inhibitor or siRNA. The relationship between PYK2 and PKCα in CORM-2-mediated responses was also differentiated by using respective inhibitors. Pretreatment with PF431396 inhibited the CORM-2-stimulated phosphorylation of PYK2 and PKCα; however, Gö6983 and Gö6976 only attenuated phosphorylation of PKCα, implying that PKCα was a downstream component of PYK2 in CORM-2-mediated responses. Both Gö6976 and Gö6983 were used to identify the PKC isoforms involved in HO-1 expression. The specificities of these inhibitors may account for the differences observed. Thus, to confirm the efficacy of pharmacological inhibitors, we also performed experiments that used the transfection with siRNA to ensure the role of PKCα in CORM-2-induced HO-1 expression. To the best of our knowledge, our results are the first to show the novel roles of PYK2 and PKCα in CORM-2-induced HO-1 expression in HPAEpiCs. These data suggest that CORM-2-induced HO-1 expression is mediated through a PYK2/ PKCα pathway in HPAEpiCs. However, how CORM-2 stimulates the phosphorylation of PKC/PYK2 in HPAEpiCs is still unknown.
The abnormal activation of MAPK has been implicated in a variety of inflammatory responses and tissue injury and the induction of several inflammatory mediators in different cell types (Alam and Gorska, 2011; Lee and Yang, 2012; Lee et al., 2013a) . In the present study, we demonstrated that ERK1/2 was required for the CORM-2-induced increase in HO-1 expression, which was attenuated by a selective MEK1/2 pharmacological inhibitor U0126 or transfection with p42 siRNA. The involvement of these kinases in CORM-2-stimulated pathways was further confirmed by showing that CORM-2 mediated phosphorylation of ERK1/2. These results are consistent with the data that show the increase in HO-1 expression in HepG2 cells (Yuan et al., 2006) and haem-mediated neuronal injury (Foresti et al., 2008) are mediated by ERK1/2. In the present study, CORM-2-stimulated phosphorylation of ERK1/2 was attenuated by pretreatment with the inhibitor of PKCα (Gö6983), PYK2 (PF431396) or MEK1/2 (U0126), suggesting that PKCα/PYK2-dependent ERK1/2 phosphorylation is crucial for CORM-2-induced increase in HO-1 expression in HPAEpiCs. These results are also consistent with several reports that MAPKs including ERK1/2 are involved in the regulation of cellular functions in response to outside stimuli in several cell types (Pawate et al., 2004; Cheng et al., 2006; Hsieh et al., 2010) . Indeed, in a previous study we and others found that inhibition of JNK1/2 or p38 MAPK also attenuates CORM-2-or curcumin-induced HO-1 expression in HTSMCs and in renal epithelial cells (Balogun et al., 2003) . The roles of these protein kinases may be involved in CORM-2-induced increase in HO-1 expression in HPAEpiCs and merit further study in the future.
AP-1 transcription factor typically consists of a combination of Jun and Fos proteins, which bind to the promoters of target genes (Vesely et al., 2009) . It is found to be responsible for the transcriptional activation of various genes that are activated by phorbol esters (such as PMA) via activation of PKC (Lee and Yang, 2012; Lee et al., 2013a) . AP-1 may be activated by PKCs and MAPKS in response to various cytokines, including TNF-α and IL-1β (Lee and Yang, 2012; Lee et al., 2013a) . The activated transcription factors interact with response elements on the HO-1 promoter to regulate gene transcription (Rochette et al., 2013) . Here, we focused on the role of th etranscription factor AP-1, which is well known to be modulated during inflammatory diseases (Sen and Packer, 1996) . By using its pharmacological inhibitor Tanshinone IIA, we demonstrated that AP-1 is involved in the CORM-2-induced HO-1 expression. The involvement of AP-1 in these responses was further verified by the results indicating that CORM-2 induced c-Fos mRNA expression via a PYK2/PKCα-dependent ERK1/2 pathway. Moreover, the roles of c-Fos/AP-1 in CORM-2-induced HO-1 expression were confirmed by transfection with c-Fos siRNA, which was found to attenuate CORM-2-induced HO-1 expression. These results are consistent with reports indicating that α-lipoic acid induces HO-1 expression in vascular smooth muscle cells (Cheng et al., 2006) and BK induces HO-1 expression in brain astrocytes (Hsieh et al., 2010) . Thus, CORM-2-induced HO-1 expression is mediated through a PYK2/PKCα/ERK1/2/AP-1 pathway in HPAEpiCs.
TNF-α has been implicated in the pathophysiology of many inflammatory lung diseases, including chronic bronchitis, COPD, ARDS and asthma . Leukocytes and monocytes isolated from BAL fluid of asthmatics were shown to release more TNF-α than those of cells from control subjects. It has been suggested that TNF-α up-regulates adhesion molecules and is directly responsible for the transendothelial migration of inflammatory cells, which is a central feature underlying inflammatory responses (Lee et al., 2013b) . In this study, we also investigated the protective effects of CORM-2 on TNF-α-induced inflammatory responses. We observed that TNF-α (0.25 mg·kg À1 body weight) induced significant pulmonary haematoma in mice. In addition, TNF-α also induced an increase in VCAM-1 expression in lung tissues and leukocyte counts in BAL fluid in mice. These responses may further lead to lung inflammatory diseases. Moreover, pretreatment with CORM-2 inhibited this TNF-α-induced increase in adhesion molecules expression and leukocyte counts in BAL fluid in mice, and this effect of CORM-2 was reversed by ZnPPIX administration by about 85%, but not completely, as compared with that of TNF-α treatment alone. These results suggest that CORM-2 may have an alternative effect independent of HO-1 that can result in the suppression of TNF-α-induced increase in VCAM-1 expression and leukocyte counts.
In conclusion, based on previous observations and our findings, we have suggested a model ( Figure 6F ) for the molecular mechanisms involved in the CORM-2-induced increase in HO-1 expression in HPAEpiCs. These findings indicating that CORM-2 induces an increase HO-1 expression imply that HO-1/CO might play a protective role in lung inflammatory diseases, and this effect is mediated via PYK2/PKCα/ERK1/2-dependent AP-1 activation in HPAEpiCs. These findings further support the application of CORM-2 as a potential intervention for the prevention or treatment of pulmonary inflammatory diseases. Thus, as the induction of HO-1 expression may hold therapeutic promise, continuous efforts towards identifying novel lung protective and anti-inflammatory compounds that target HO-1 and in vivo models that can properly evaluate the efficacy of these agents will be warranted.
